{
    "nctId": "NCT03521245",
    "briefTitle": "Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer",
    "officialTitle": "Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Tumor response by RECIST v1.1 or pathological response according to Chevallier system",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* adult females\n* histologically confirmed HER2-positive breast cancer\n* available FFPE samples of breast cancer tissue\n* patients treated with Trastuzumab alone or in combination(s) with other regimens of chemotherapy with known outcome according to RECIST 1.1\n* stage II or more\n* patients who have signed an informed consent\n\nExclusion Criteria:\n\n* less than 70% of intact tumor cells in available FFPE samples",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}